VRDN Valuation

Viridian Therapeutics Inc

Add to Watchlist

Advanced Chart

18.660

+0.12(0.647%)1D

Overview
Forecast
Valuation
Earnings

VRDN Relative Valuation

VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRDN is overvalued; if below, it's undervalued.

Historical Valuation

Viridian Therapeutics Inc (VRDN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 92.72 is considered Undervalued compared with the five-year average of -4.54. The fair price of Viridian Therapeutics Inc (VRDN) is between 759.70 to 1397.17 according to relative valuation methord. Compared to the current price of 18.66 USD , Viridian Therapeutics Inc is Undervalued By 97.54%.

Relative Value

Fair Zone

759.70-1397.17

Current Price：18.66

97.54%

Undervalued

-4.34

Trailing

Forward

-4.59

EV/EBITDA

Viridian Therapeutics Inc. (VRDN) has a current EV/EBITDA of -4.59. The 5-year average EV/EBITDA is -3.34. The thresholds are as follows: Strongly Undervalued below -7.41, Undervalued between -7.41 and -5.38, Fairly Valued between -1.31 and -5.38, Overvalued between -1.31 and 0.72, and Strongly Overvalued above 0.72. The current Forward EV/EBITDA of -4.59 falls within the Historic Trend Line -Fairly Valued range.

-2.95

EV/EBIT

Viridian Therapeutics Inc. (VRDN) has a current EV/EBIT of -2.95. The 5-year average EV/EBIT is -2.99. The thresholds are as follows: Strongly Undervalued below -5.65, Undervalued between -5.65 and -4.32, Fairly Valued between -1.66 and -4.32, Overvalued between -1.66 and -0.34, and Strongly Overvalued above -0.34. The current Forward EV/EBIT of -2.95 falls within the Historic Trend Line -Fairly Valued range.

92.72

Viridian Therapeutics Inc. (VRDN) has a current PS of 92.72. The 5-year average PS is 2554.98. The thresholds are as follows: Strongly Undervalued below -2670.40, Undervalued between -2670.40 and -57.71, Fairly Valued between 5167.67 and -57.71, Overvalued between 5167.67 and 7780.36, and Strongly Overvalued above 7780.36. The current Forward PS of 92.72 falls within the Historic Trend Line -Fairly Valued range.

-4.53

P/OCF

Viridian Therapeutics Inc. (VRDN) has a current P/OCF of -4.53. The 5-year average P/OCF is -4.12. The thresholds are as follows: Strongly Undervalued below -8.70, Undervalued between -8.70 and -6.41, Fairly Valued between -1.84 and -6.41, Overvalued between -1.84 and 0.45, and Strongly Overvalued above 0.45. The current Forward P/OCF of -4.53 falls within the Historic Trend Line -Fairly Valued range.

-4.69

P/FCF

Viridian Therapeutics Inc. (VRDN) has a current P/FCF of -4.69. The 5-year average P/FCF is -4.41. The thresholds are as follows: Strongly Undervalued below -8.28, Undervalued between -8.28 and -6.35, Fairly Valued between -2.48 and -6.35, Overvalued between -2.48 and -0.54, and Strongly Overvalued above -0.54. The current Forward P/FCF of -4.69 falls within the Historic Trend Line -Fairly Valued range.

Viridian Therapeutics Inc (VRDN) has a current Price-to-Book (P/B) ratio of 4.64. Compared to its 3-year average P/B ratio of 4.33 , the current P/B ratio is approximately 7.27% higher. Relative to its 5-year average P/B ratio of 3.95, the current P/B ratio is about 17.52% higher. Viridian Therapeutics Inc (VRDN) has a Forward Free Cash Flow (FCF) yield of approximately -20.45%. Compared to its 3-year average FCF yield of -15.75%, the current FCF yield is approximately 29.86% lower. Relative to its 5-year average FCF yield of -21.12% , the current FCF yield is about -3.16% lower.

4.64

P/B

Median3y

4.33

Median5y

3.95

-20.45

FCF Yield

Median3y

-15.75

Median5y

-21.12

Competitors Valuation Multiple

The average P/S ratio for VRDN's competitors is 22.19, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 92.72, which is 317.81% above the industry average. Given its robust revenue growth of 4.17%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VRDN.O

Viridian Therapeutics Inc

ARS Pharmaceuticals Inc

Performance Decomposition

Market capitalization of VRDN increased by 26.29% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -90.27K to -134.31K.

The secondary factor is the Revenue Growth, contributed 4.17%to the performance.

Overall, the performance of VRDN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

4.17%

72.00K → 75.00K

Revenue Growth

48.79%

-90.27K → -134.31K

Margin Expansion

-26.67%

-7.10 → -5.20

P/E Change

26.29%